173 related articles for article (PubMed ID: 35199485)
1. Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole.
Aiuchi N; Nakagawa J; Sakuraba H; Takahata T; Kamata K; Saito N; Ueno K; Ishiyama M; Yamagata K; Kayaba H; Niioka T
Pharmacol Res Perspect; 2022 Apr; 10(2):e00935. PubMed ID: 35199485
[TBL] [Abstract][Full Text] [Related]
2. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.
Niioka T; Fujishima N; Abumiya M; Yamashita T; Ubukawa K; Nara M; Fujishima M; Takahashi N; Miura M
Ther Drug Monit; 2017 Oct; 39(5):514-521. PubMed ID: 28834922
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
[TBL] [Abstract][Full Text] [Related]
4. Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation.
Nakagawa J; Kinjo T; Aiuchi N; Ueno K; Tomita H; Niioka T
Eur J Clin Pharmacol; 2023 Jan; 79(1):127-135. PubMed ID: 36399204
[TBL] [Abstract][Full Text] [Related]
5. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
Yamada T; Mino Y; Naito T; Kawakami J
J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
[TBL] [Abstract][Full Text] [Related]
6. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
[TBL] [Abstract][Full Text] [Related]
7. Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population.
Li Y; Zhang Y; Zhao J; Bian J; Zhao Y; Hao X; Liu B; Hu L; Liu F; Yang C; Feng Y; Huang L
J Chemother; 2024 May; 36(3):179-189. PubMed ID: 37599449
[TBL] [Abstract][Full Text] [Related]
8. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and Adsorptive Analyses of Administration of Oral Voriconazole Suspension via Enteral Feeding Tube in Intensive Care Unit Patients.
Tanaka R; Eto D; Goto K; Ohchi Y; Yasuda N; Suzuki Y; Tatsuta R; Kitano T; Itoh H
Biol Pharm Bull; 2021; 44(5):737-741. PubMed ID: 33952830
[TBL] [Abstract][Full Text] [Related]
10. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
[TBL] [Abstract][Full Text] [Related]
11. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.
Zeng G; Wang L; Shi L; Li H; Zhu M; Luo J; Zhang Z
Eur J Clin Pharmacol; 2020 Apr; 76(4):515-523. PubMed ID: 31932875
[TBL] [Abstract][Full Text] [Related]
12. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
[TBL] [Abstract][Full Text] [Related]
13. Impact of
Ebrahimpour S; Namazi S; Mohammadi M; Nikbakht M; Hadjibabaie M; Masoumi HT; Ghavamzadeh A
J Res Pharm Pract; 2017; 6(3):151-157. PubMed ID: 29026840
[TBL] [Abstract][Full Text] [Related]
14. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.
Imamura CK; Furihata K; Okamoto S; Tanigawara Y
J Clin Pharmacol; 2016 Apr; 56(4):408-13. PubMed ID: 26239045
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Drug Monitoring of Oral Voriconazole in an Infant Less than Six Months of Age and Pharmacokinetics Changes Induced by Development of CYP2C19 in the Growth Process: A Novel Case Report.
Yamaguchi A; Tazawa Y; Ueki M; Yamada M; Manabe A; Sugawara M; Takekuma Y
Yakugaku Zasshi; 2023; 143(6):545-549. PubMed ID: 37258188
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
[TBL] [Abstract][Full Text] [Related]
17. [The Application Study of Voriconazole and Its Metabolites Concentration Monitoring in Allogeneic Hematopoietic Stem Cell Transplantation Patients].
Wang HC; Wang L; Li M; Shi L; Sun HH; Liu HX; Ou HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):945-951. PubMed ID: 38926993
[TBL] [Abstract][Full Text] [Related]
18. Positive correlation between voriconazole trough concentrations and C-reactive protein levels in patients with chronic pulmonary aspergillosis: A retrospective cohort study.
Miyakawa-Tanaka K; Suzuki J; Hirasawa Y; Nakamura S; Takeda K; Narumoto O; Matsui H
J Infect Chemother; 2023 Jul; 29(7):683-687. PubMed ID: 36965708
[TBL] [Abstract][Full Text] [Related]
19. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
[TBL] [Abstract][Full Text] [Related]
20. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
